



Simon Bell
Australian Competition & Consumer Commission
Level 2, 23 Marcus Clarke Street
Canberra, ACT 2601

30 April 2020

Medicines Australia application for authorisation AA1000486 – request for update

Dear Mr Bell

Thank you for your inquiry dated 29 April 2020 in relation to the supply of essential medicines and the interim authorisation granted to Medicines Australia to implement a coordinated strategy (the Proposed Conduct).

Novo Nordisk's key priority is to safeguard the continued supply of our lifesaving medicines to people living with diabetes and other serious chronic diseases. Currently, we are not experiencing any supply constraints in our global production, distribution or storage (warehouses). We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.

Consequently, we confirm Novo Nordisk has not engaged in the Proposed Conduct and does not at this time anticipate a need to engage in the Proposed Conduct.

If you have any further questions or concerns, you are very welcome to contact us.

Kind Regards



Jeppe Theisen
VP and General Manager

**Novo Nordisk
Pharmaceuticals Pty.
Ltd.**

Level 3
21 Solent Circuit
Baulkham Hills NSW 2153
Australia

Telephone:
+61 2 8858 3600
Direct dial:

Telefax:
+61 2 8858 3799

E-mail:

Internet:
www.novonordisk.com.au